In Vitro and in Vivo Pharmacological Characterization of the Neuropeptide S Receptor Antagonist [d-Cys(tBu)5]Neuropeptide S

Valeria Camarda, Anna Rizzi, Chiara Ruzza, Silvia Zucchini, Giuliano Marzola, Erika Marzola, Remo Guerrini, Severi Salvadori, Rainer K. Reinscheid, Domenico Regoli, and Girolamo Calò

Department of Experimental and Clinical Medicine, Section of Pharmacology, Neuroscience Center, National Institute of Neuroscience (V.C., A.R., C.R., S.Z., G.M., D.R., G.C.) and Department of Pharmaceutical Sciences and Biotechnology Center (E.M., R.G., S.S.), University of Ferrara, Ferrara, Italy; and Department of Pharmaceutical Sciences, University of California, Irvine, California (R.K.R.)

Received July 23, 2008; accepted October 28, 2008

ABSTRACT

Neuropeptide S (NPS) was identified as the endogenous ligand of an orphan receptor now referred to as the NPS receptor (NPSR). In response to a structure-activity study performed on NPS Gly5, the NPSR ligand [d-Cys(tBu)5]NPS was identified. [d-Cys(tBu)5]NPS up to 100 μM did not stimulate calcium mobilization in human embryonic kidney (HEK) 293 cells stably expressing the mouse NPSR; however, in a concentration-dependent manner, the peptide inhibited the stimulatory effects elicited by 10 and 100 nM NPS (pA2, 6.62). In Schild analysis experiments [d-Cys(tBu)5]NPS (0.1–100 μM) produced a concentration-dependent and parallel rightward shift of the concentration-response curve to NPS, showing a pA2 value of 6.44. Ten micromolar [d-Cys(tBu)5]NPS did not affect signaling at seven NPSR unrelated G-protein-coupled receptors. In the mouse righting reflex (RR) recovery test, NPS given at 0.1 nmol i.c.v. reduced the percentage of animals losing the RR in response to 15 mg/kg diazepam and their sleeping time. [d-Cys(tBu)5]NPS (1–10 nmol) was inactive per se but dose-dependently antagonized the arousal-promoting action of NPS. Finally, NPSR-deficient mice were similarly sensitive to the hypnotic effects of diazepam as their wild-type littermates. However, the arousal-promoting action of 1 nmol NPS could be detected in wild-type but not in mutant mice. In conclusion, [d-Cys(tBu)5]NPS behaves both in vitro and in vivo as a pure and selective NPSR antagonist but with moderate potency. Moreover, using this tool together with receptor knockout mice studies, we demonstrated that the arousal-promoting action of NPS is because of the selective activation of the NPSR protein.

Neuropeptide S (NPS) is a newly discovered peptide that binds and activates a previously orphan G-protein-coupled receptor, now referred to as NPSR (Xu et al., 2004). NPS and NPSR are expressed at high levels in the brain and in a few peripheral tissues (Xu et al., 2004). The distribution of NPSR and the neurochemical characteristics of neurons expressing NPS in the rat brain were recently reported by the same group (Xu et al., 2007). In cells expressing recombinant NPSR, NPS was demonstrated to stimulate calcium mobilization and cAMP levels (Xu et al., 2004; Reinscheid et al., 2005). Little is known regarding the effects of NPS in tissues expressing the native NPSR. However, it has been reported recently that NPS modulates neurotransmitter release from mouse frontal cortex synaptosomes by inhibiting noradrenaline, serotonin, and glycine outflow (Raiteri et al., 2008). As far as in vivo actions of NPS are concerned, the following animal studies demonstrated that the NPS/NPSR system modulates several biological functions, including locomotor activity (Xu et al., 2004; Smith et al., 2006; Rizzi et al., 2008), wakefulness (Xu et al., 2004; Rizzi et al., 2008), anxiety (Xu et al., 2004; Leonard et al., 2008; Rizzi et al., 2008; Vitale et al., 2008), and food intake (Beck et al., 2005; Ciccocioppo et al., 2006; Niimi, 2006; Smith et al., 2006).

To deeply investigate the physiological and pathological roles played by the NPS/NPSR system and to evaluate possible therapeutic indications of novel drugs interacting with

ABBREVIATIONS: NPS, neuropeptide S; NPSR, NPS receptor; SHA 66, 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-alpyrazine-7-carboxylic acid benzylamide; SHA 68, 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-alpyrazine-7-carboxylic acid 4-fluoro-benzylamide; HEK, human embryonic kidney; HEK293, nonNPSR, HEK293 cells expressing the mouse NPSR; RR, righting reflex recovery; NPSR(+/−), NPSR knockout mice; PCR, polymerase chain reaction; CHO, Chinese hamster ovary.
NPSR, the identification of selective NPSR ligands, particularly antagonists, is mandatory. Until now, the only NPSR antagonists described in literature are two closely related bicyclic piperazines, SHA 66 and SHA 68 (Okamura et al., 2008). These compounds behaved as selective, competitive, and fairly potent \( pA_2 \approx 7.5 \) NPSR antagonists in calcium mobilization studies performed on cells expressing the recombinant receptor (Okamura et al., 2008). In vivo in mice, 50 mg/kg SHA 68 was able to partially counteract the stimulatory effects of NPS on locomotion. However, this molecule has only limited blood brain barrier penetration, and this may explain why only half of the motor-activating effect of SHA 68 was able to partially counteract the stimulatory effects of NPS on locomotion. However, this molecule has only limited blood brain barrier penetration, and this may explain why only half of the motor-activating effect of NPS was blocked at relatively high doses of antagonist (Okamura et al., 2008). Despite this, SHA 68 certainly represents a useful tool for NSP-NPSR system investigations as demonstrated by recent studies in which NPS evokes anxiolytic effects and facilitates extinction of conditioned fear responses when administered into the amygdala in mice, whereas SHA 68 exerts functionally opposing responses, indicating that the endogenous system is involved in anxiety behavior and extinction (Jungling et al., 2008).

To identify novel interesting ligands for the NPSR receptor, we and others performed structure-activity studies on the NPS peptide sequence, which demonstrated that the N-terminal part of the peptide, in particular the sequence Phe\(^2\)-Arg\(^3\)-Asn\(^4\), is crucial for biological activity (Bernier et al., 2006; Roth et al., 2006). Subsequent studies were focused on conformation-activity relationships (Tancredi et al., 2007) and on Phe\(^2\) of the NPS sequence (Camarda et al., 2008). In the frame of these studies, some NPSR peptide ligands were identified, including [Ala\(^3\)]NPS (Roth et al., 2006), [Alb\(^4\)]NPS (Tancredi et al., 2007), and [4,4'-biphenyl-Ala\(^{2}\)Ala\(^{2}\)]NPS (Camarda et al., 2008), which behaved as partial agonists in vitro in the calcium mobilization assay. [Ala\(^3\)]NPS was also evaluated in vivo where it partially blocked the stimulatory effect of NPS on mice locomotor behavior (Calo et al., 2006) and the inhibitory action of NPS on palatable food intake in rats (Ciccocioppo et al., 2006).

In a structure-activity study on position 5 of NPS, we identified [p-Cys(tBu)\(^5\)]NPS as a peptidic NPSR receptor ligand. In the present study, [p-Cys(tBu)\(^5\)]NPS has been characterized pharmacologically in vitro using HEK293 cells stably expressing the mouse NPSR (HEK293\(_{m\text{NPSR}}\)) and the fluorometric imaging plate reader FlexStation II and in vivo investigating its effects in the mouse righting reflex (RR) recovery test. Moreover, in the RR test, under the same experimental conditions, the phenotype and sensitivity to NPS were assessed in wild-type [NPSR\(^{+/+}\)] mice and in NPSR-deficient mice [NPSR\(^{-/-}\)].

### Materials and Methods

**Cell Culture.** HEK293\(_{m\text{NPSR}}\) Cells were generated as described previously (Reinscheid et al., 2005) and maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 2 mM l-glutamine, and hygromycin B (100 mg/ml) and cultured at 37°C in 5% CO\(_2\) humidified air. HEK293\(_{m\text{NPSR}}\) cells were seeded at a density of 50,000 cells/well into poly-D-lysine-coated 96-well black, clear-bottom plates.

**Calcium Mobilization Experiments.** The following day, the cells were incubated with medium supplemented with 2.5 mM probenecid, 3 \( \mu \)M of the calcium-sensitive fluorescent dye Fluo-4 acetoxymethyl ester, and 0.01% Pluronic acid for 30 min at 37°C. After that time, the loading solution was aspirated, and 100 \( \mu \)l/well assay buffer (Hanks' balanced salt solution) supplemented with 20 mM HEPES, 2.5 mM probenecid, and 500 \( \mu \)M Brilliant Black (Aldrich Chemical Co., Milwaukee, WI) was added. Concentrated solutions (1 mM) of NPS and [D-Cys(tBu)\(^5\)]NPS were made in bidistilled water and kept at \(-20^\circ\)C. Serial dilutions were carried out in Hanks' balanced salt solution/20 mM HEPES buffer containing 0.02% bovine serum albumin fraction V. After placing both plates (cell culture and master plate) into the fluorometric imaging plate reader FlexStation II (Molecular Devices, Sunnyvale, CA), fluorescence changes were measured at room temperature (\(-25^\circ\)C). On-line additions were carried out in a volume of 50 \( \mu \)l/well. The in vitro data were expressed as mean ± S.E.M. of at least four independent experiments made in duplicate. Maximum change in fluorescence, expressed in percentage of baseline fluorescence, was used to determine agonist response. Nonlinear regression analysis using GraphPad Prism software (version 4.0; GraphPad Software Inc., San Diego, CA) allowed logistic iterative fitting of the resultant responses and the calculation of agonist potencies and maximal effects. Agonist potencies are given as \( pEC_{50} \) (the negative logarithm to base 10 of the molar concentration of an agonist that produces 50% of the maximal possible effect). [D-Cys(tBu)\(^5\)]NPS antagonist properties were evaluated in in vivoh experiments, and the antagonist potency was expressed as \( pK_A \), derived from the following equation: \( K_a = IC_{50}/[2 + ([A]/IC_{50})^{1/(n-1)}] \), where \( IC_{50} \) is the concentration of antagonist that produces 50% inhibition of the agonist response, [A] is the concentration of the agonist, \( EC_{50} \) is the concentration of agonist producing a 50% maximal response, and \( n \) is the Hill coefficient.

**Animals.** All experimental procedures adopted for in vivo studies complied with the standards of the European Communities Council directives (86/609/EEC) and national regulations (D.L. 116/92). Male Swiss mice (3–4 months old; weight, 30–38 g) and 129S6/SvEv Taconic NPSR\(^{+/+}\) and NPSR\(^{-/-}\) littermates (4–6 months; weight, 20–28 g) were used. They were housed in 425 × 266 × 155-mm cages (Tecniplast, Montreal, QC, Canada), under standard conditions (22°C, 55°C humidity, 12-h light/dark cycle, lights on at 7:00 AM) with food (MIL, standard diet; Morini, Reggio Emilia, Italy) and water ad libitum for at least 10 days before the experiments began. Each animal was used only once. NPS and [D-Cys(tBu)\(^5\)]NPS were given intracerebroventricularly. Intracerebroventricular injections (2 \( \mu \)l/mouse) were given after anesthesia under light (just sufficient to produce a loss of the righting reflex) into the left ventricle according to the procedure described by Laursen and Belknap (1986) and routinely adopted in our laboratory (Rizzi et al., 2001). All procedures were randomized across test groups.

**Generation of NPSR\(^{-/-}\) Mice.** NPSR\(^{+/+}\) and NPSR\(^{-/-}\) littermates were obtained by mating heterozygous NPSR\(^{+/+}\) 129S6/SvEv mice (Taconic Farms, Germantown, NY), and all were genotyped using the polymerase chain reaction (PCR) to determine the target disruption of the NPSR gene. DNAs were prepared from tail biopsies using the Eazy Nucleic Acid Isolation Tissue DNA Kit (Omega Bio-tek, Norcross, GA). One microliter of genomic DNA was used to amplify the target disruption of the NPSR gene. DNAs were prepared from tail biopsies using the Eazy Nucleic Acid Isolation Tissue DNA Kit (Omega Bio-tek, Norcross, GA). One microliter of genomic DNA was used to amplify the target disruption of the NPSR gene. DNAs were prepared from tail biopsies using the Eazy Nucleic Acid Isolation Tissue DNA Kit (Omega Bio-tek, Norcross, GA).
total volume. The reaction was placed in a thermal cycler and heated to 94°C for 1 min. The reaction was allowed to proceed for 39 cycles as follows: 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min. Finally, the reaction was heated to 72°C for 2 min and then stored at 4°C. The reaction products were separated in 1% agarose by horizontal gel electrophoresis in Tris acetate-EDTA buffer, stained with ethidium bromide, and photographed under UV light.

**Mouse Righting Reflex Recovery Test.** The RR assay was performed according to the procedures described previously in detail (Rizzi et al., 2008). In brief, mice were given an intraperitoneal injection of 15 mg/kg diazepam. When the animals lost the RR, they were placed in a plastic cage, and the time was recorded by an expert observer blind to drug treatments. Animals were judged to have regained the RR response when they could right themselves three times within 30 s. Sleeping time is defined as the amount of time between the loss and regaining of the RR; it was rounded to the nearest minute. The ability of NPS (0.1 nmol i.c.v.) and [D-Cys(tBu)⁵]NPS (1 and 10 nmol i.c.v.) to modify the number (percentage) of animals responding to 15 mg/kg diazepam and their sleeping time (minutes) were evaluated. NPS and [D-Cys(tBu)⁵]NPS were administered 5 min before the injection of diazepam.

**Drugs and Reagents.** NPS and [D-Cys(tBu)⁵]NPS were synthesized according to published methods (Camarda et al., 2008) using Fmoc/tBu chemistry with a SYRO XP multiple peptide synthesizer (Syro-MultiSynTech, Bochum, Germany). Crude peptides were purified by preparative reversed-phase high-performance liquid chromatography, and the purity was checked by analytical high-performance liquid chromatography and mass spectrometry using a matrix-assisted laser desorption ionization time of flight (Bruker Daltonics, Billerica, MA) and an ESI Micromass ZMD-2000 mass spectrometer (Waters, Milford, MA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO). The vehicle used for injecting NPS and [D-Cys(tBu)⁵]NPS was 0.9% saline.

**Terminology and Statistical Analysis.** The pharmacological terminology adopted in this article is consistent with International Union of Basic and Clinical Pharmacology recommendations (Neubig et al., 2003). Data are expressed as mean ± S.E.M. of n experiments/animal. For agonist and antagonist potencies, 95% confidence limits were given. Data were analyzed using the Student’s t test, as specified in the figure legends. Differences were considered statistically significant when p < 0.05.

**Results**

**Calcium Mobilization Assay.** In the calcium mobilization assay performed on HEK293nNPSR cells, NPS increased the intracellular calcium concentrations in a concentration-dependent manner, with pEC⁵₀ and Eₘₐₓ values of 8.86 (CL₉⁵/₉₅, 8.46–9.26) and 380 ± 50% over the basal, respectively (Fig. 1, top). [D-Cys(tBu)⁵]NPS, up to concentrations as high as 100 μM, was found inactive (Fig. 1, top). Inhibition-response curves to [D-Cys(tBu)⁵]NPS (0.1 nM–100 μM) were then performed against the stimulatory effect of NPS at 10 and 100 nM, corresponding to submaximal and maximal concentrations, respectively. As shown in Fig. 1, bottom, [D-Cys(tBu)⁵]NPS concentration-dependently inhibited 10 and 100 nM NPS effects, with pIC₅₀ values of 5.75 and 4.64 (for the latter assuming a complete inhibition), respectively. A [D-Cys(tBu)⁵]NPS pKᵢ value of 6.62 (CL₉⁵/₉₅, 6.40–6.84) was derived from these experiments.

To get information on the nature of the antagonist action exerted by [D-Cys(tBu)⁵]NPS, the classical Schild analysis was also performed. As depicted in Fig. 2, top, [D-Cys(tBu)⁵]NPS, in the range 0.1 to 100 μM, did not have any effect per se but produced a rightward shift of the concentration-response curve to NPS in a concentration-dependent manner, whereas the curves remained parallel to the control and reached similar maximal effects. The corresponding Schild plot, which was linear (r² = 0.99) with a slope of 0.97 ± 0.07, is shown in Fig. 2, bottom. The extrapolated pA₂ value was 6.44.

Finally, [D-Cys(tBu)⁵]NPS selectivity of action was investigated by challenging the peptide against a panel of G-protein-coupled receptors (Table 1). These include native muscarinic receptors expressed in HEK293 cells, native PAR-2 receptors expressed in A549 cells, and recombinant human NK-1, UT, and opioid receptors expressed in CHO cells. In these experiments, [D-Cys(tBu)⁵]NPS did not stimulate calcium mobilization up to 10 μM and did not modify the concentration-response curves to receptor agonists (Table 1).

**PCR Analysis of Tail Biopsy DNA from Offspring Obtained by Mating Heterozygous NPSR(+/−) Mice.** All the results obtained in this study were performed using NPSR(+/+) and NPSR(−/−) littermates; all the mice were genotyped and divided in two experimental groups depending on the presence of different PCR products. As shown in Fig. 3, the PCR amplification of a 418-bp DNA fragment identifies a homozygous wild-type NPSR(+/+) mouse, whereas the 599-bp DNA fragment corresponds to a NPSR(−/−) mouse. Amplification of both DNA fragments is related to a heterozygous NPSR(+/−) mouse (Fig. 3).

**Righting Reflex Recovery Test.** As shown in Fig. 4, intraperitoneal injection of diazepam at the hypnotic dose of 15 mg/kg produced loss of the RR in 92% of the mice, and approximately 105 min were needed to regain this reflex.
NPS injected intracerebroventricularly at 0.1 nmol reduced the percentage of animals responding to diazepam to 58% and their sleeping time to approximately 50 min. On the contrary, the administration of [d-Cys(tBu)5]NPS at 1 and 10 nmol did not significantly modify the hypnotic effect of diazepam, either in terms of percentage of animals losing the RR or sleeping time. When 1 nmol [d-Cys(tBu)5]NPS was co-administered with NPS, it did not significantly modify the action of NPS, and their sleeping time to approximately 50 min. On the contrary, when tested in [d-Cys(tBu)5]NPS at concentrations as high as 100 µM did not stimulate calcium mobilization in HEK293NmNPSR cells but was able to completely inhibit, in a concentration-dependent manner, the stimulatory effect of NPS. These results demonstrate that [d-Cys(tBu)5]NPS lacks efficacy and behaves as a pure NPSR antagonist. In inhibition-response curve experiments, [d-Cys(tBu)5]NPS antagonized NPS effects, with pIC50 values (5.75 versus 10 nM NPS, 4.64 versus 100 nM NPS) clearly influenced by the concentration of agonist, thus suggesting a competitive type of interaction (Kenakin, 2004). This was confirmed by classical Schild analysis where the peptide produced a concentration-dependent rightward shift of the concentration-response curves to NPS without modifying its maximal effects. The estimated potency of [d-Cys(tBu)5]NPS in the two series of experiments, namely Schild plot (pA2, 6.44) and inhibition experiments (pKb, 6.62), is virtually superimposable and allows the classification of this ligand as a moderate-potency, pure, and competitive antagonist.

Under the same experimental conditions, 10 µM [d-Cys(tBu)5]NPS was found to be inactive both as agonist and antagonist at different G-protein-coupled receptors including muscarinic, opioid, NK-1, UT, and PAR-2 receptors. These results certainly allow the exclusion of the possibility that the antagonist action of [d-Cys(tBu)5]NPS versus NPS can be because of a nonspecific inhibitory effect on calcium signaling. However, the panel of receptors used is probably not enough for firmly classifying [d-Cys(tBu)5]NPS as a selective NPSR antagonist. On the other hand, it is worthy of mention that [d-Cys(tBu)5]NPS was generated by substituting a single residue into a 20-amino acid-long peptide characterized by high selectivity of action (Xu et al., 2004) and whose primary sequence is highly conserved among animal species (Reinscheid, 2007). These considerations make the possibility that [d-Cys(tBu)5]NPS will be adopted as a lead structure to develop more potent NPSR peptide antagonists. In addition, the present study provides converging in vivo evidence from both receptor antagonist and knockout studies demonstrating that the arousal-promoting action of NPS is solely because of selective NPSR activation.

The in vitro pharmacological features of [d-Cys(tBu)5]NPS were assessed in cells expressing the murine NPSR measuring intracellular calcium levels in a similar manner as we and others did in previous studies (Reinscheid et al., 2005; Roth et al., 2006; Tancredi et al., 2007; Camarda et al., 2008; Okamura et al., 2008). [d-Cys(tBu)5]NPS at concentrations as high as 100 µM did not stimulate calcium mobilization in HEK293NmNPSR cells but was able to completely inhibit, in a concentration-dependent manner, the stimulatory effect of NPS. These results demonstrate that [d-Cys(tBu)5]NPS lacks efficacy and behaves as a pure NPSR antagonist. In inhibition-response curve experiments, [d-Cys(tBu)5]NPS antagonized NPS effects, with pIC50 values (5.75 versus 10 nM NPS, 4.64 versus 100 nM NPS) clearly influenced by the concentration of agonist, thus suggesting a competitive type of interaction (Kenakin, 2004). This was confirmed by classical Schild analysis where the peptide produced a concentration-dependent rightward shift of the concentration-response curves to NPS without modifying its maximal effects. The estimated potency of [d-Cys(tBu)5]NPS in the two series of experiments, namely Schild plot (pA2, 6.44) and inhibition experiments (pKb, 6.62), is virtually superimposable and allows the classification of this ligand as a moderate-potency, pure, and competitive antagonist.

Under the same experimental conditions, 10 µM [d-Cys(tBu)5]NPS was found to be inactive both as agonist and antagonist at different G-protein-coupled receptors including muscarinic, opioid, NK-1, UT, and PAR-2 receptors. These results certainly allow the exclusion of the possibility that the antagonist action of [d-Cys(tBu)5]NPS versus NPS can be because of a nonspecific inhibitory effect on calcium signaling. However, the panel of receptors used is probably not enough for firmly classifying [d-Cys(tBu)5]NPS as a selective NPSR antagonist. On the other hand, it is worthy of mention that [d-Cys(tBu)5]NPS was generated by substituting a single residue into a 20-amino acid-long peptide characterized by high selectivity of action (Xu et al., 2004) and whose primary sequence is highly conserved among animal species (Reinscheid, 2007). These considerations make the possibility that [d-Cys(tBu)5]NPS will be adopted as a lead structure to develop more potent NPSR peptide antagonists. In addition, the present study provides converging in vivo evidence from both receptor antagonist and knockout studies demonstrating that the arousal-promoting action of NPS is solely because of selective NPSR activation.

The present findings demonstrate that [d-Cys(tBu)5]NPS behaves as a pure, moderate potency, competitive, and selective NPSR antagonist. These features make [d-Cys(tBu)5]NPS a useful tool for future studies on the roles played by the NPS/NPSR system in physiology and pathology. Moreover, [d-Cys(tBu)5]NPS will be adopted as a lead structure to develop more potent NPSR peptide antagonists. In addition, the present study provides converging in vivo evidence from both receptor antagonist and knockout studies demonstrating that the arousal-promoting action of NPS is solely because of selective NPSR activation.
Selectivity profile of [D-Cys(tBu)₅]NPS at seven different G-protein-coupled receptors

Data are mean ± S.E.M. of three separate experiments performed in duplicate. The chimeric protein α₁₄₃ (Coward et al., 1999) was used to force opioid receptors to couple with the calcium pathway.

<table>
<thead>
<tr>
<th>Cell Lines</th>
<th>Receptor</th>
<th>Agonist</th>
<th>Control</th>
<th>[D-Cys(tBu)₅]NPS (10 μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>pEC₅₀</td>
<td>Eₐ₅₀ ± S.E.M.</td>
</tr>
<tr>
<td>HKE293</td>
<td>Native muscarinic</td>
<td>Carbachol</td>
<td>5.60 (5.21–5.69)</td>
<td>309 ± 51</td>
</tr>
<tr>
<td>CHO</td>
<td>Recombinant hNK-1</td>
<td>Substance P</td>
<td>10.26 (9.88–10.64)</td>
<td>122 ± 15</td>
</tr>
<tr>
<td>CHO</td>
<td>Recombinant hUT</td>
<td>Urotensin-II</td>
<td>8.31 (7.62–9.00)</td>
<td>224 ± 21</td>
</tr>
<tr>
<td>CHO-α₁₄₃</td>
<td>Recombinant hMOP</td>
<td>DermoPH</td>
<td>7.98 (7.85–8.11)</td>
<td>186 ± 11</td>
</tr>
<tr>
<td>CHO-α₁₄₃</td>
<td>Recombinant hDOP</td>
<td>[α-Pen⁶,β-Pen⁷]-enkephalin</td>
<td>8.63 (8.41–8.84)</td>
<td>169 ± 26</td>
</tr>
<tr>
<td>CHO-α₁₄₃</td>
<td>Recombinant hKOP</td>
<td>Dynorphin A</td>
<td>8.11 (7.72–8.50)</td>
<td>143 ± 12</td>
</tr>
<tr>
<td>A549</td>
<td>Native hPAR-2</td>
<td>SLIGKV-NH₂</td>
<td>4.66 (4.43–4.89)</td>
<td>449 ± 25</td>
</tr>
</tbody>
</table>

The Neuropeptide S Receptor Antagonist [D-Cys(tBu)₅]NPS 553

peptidergic arousal-promoting system (Bingham et al., 2006); in fact, orexin receptor antagonists not only prolonged barbiturate sleeping time in rats (Kushikata et al., 2003) and emergence from general anesthesia in mice (Kelz et al., 2008) but are also able per se to promote sleep in rats, dogs, and humans (Brisbare-Roch et al., 2007). It is clear that further studies are needed to firmly understand the role of the endogenous NPS/NPSR system in the regulation of wakefulness and sleep functions.

NPSR knockout mice were recently generated (Allen et al., 2006) to investigate the possible involvement of this receptor in respiratory diseases such as asthma (Laitinen et al., 2004). However, the elegant study performed by Allen et al. (2006) failed to support a direct contribution of NPSR to asthma pathogenesis. No data from receptor knockout studies are yet available regarding the involvement of NPSR in the control of central functions. Here, we used NPSR(+/+) and NPSR(−/−) mice for investigating their phenotype and sensitivity to NPS in the RR assay. These mice were more sensitive than Swiss mice to the hypnotic effect of diazepam, as suggested by the huge difference in sleeping time induced by the benzodiazepine (approximately 200 and 100 min, respectively) and by the fact that NPS reduced the percentage of animals losing the RR in response to diazepam in Swiss but not in NPSR(+/+) mice. This diverse diazepam sensitivity can be due to the difference in genetic background (Swiss versus 129Sv/Ev) and/or age (3–4 versus 4–6 months).

Results obtained from receptor knockout studies perfectly match those from antagonist studies. In fact, no differences were observed between NPSR(+/+) and NPSR(−/−) mice in terms of diazepam-induced sleeping time, and this parallels the lack of effect of [D-Cys(tBu)₅]NPS per se in the RR test, corroborating the proposal that, under the present experimental conditions, the endogenous NPS/NPSR system is not activated. Moreover, the supraspinal administration of NPS reduced diazepam-induced sleeping time in NPSR(+/+) but not in NPSR(−/−) mice, and this parallels the lack of effect of NPS in the presence of [D-Cys(tBu)₅]NPS, corroborating the proposal that the mechanism by which NPS promotes arousal is the selective activation of the NPSR protein.

In conclusion, the present study describes the in vitro and in vivo pharmacological features of [D-Cys(tBu)₅]NPS and demonstrates that this molecule behaves as a moderate potency, pure, competitive, and selective NPSR antagonist. Moreover, using this tool together with receptor knockout mice studies, it has been demonstrated that the arousal-promoting action of NPS is because of the selective activation
of the NPSR protein. In the near future, the use of peptide (i.e., [D-Cys(tBu)5]NPS) and nonpeptide (i.e., SHA 68, Okamura et al., 2008) NPSR antagonists together with NPSR(+/+)/NPSR(−/−) animals will allow for a more detailed investigation of the NPS/NPSR system in several important central functions, such as sleep/wakefulness cycles, the response to stress, anxiety, and regulation of food intake. This information will be crucial for validating the therapeutic potential of new drugs acting as NPSR ligands.

References
Allen IC, Pace AJ, Jania LA, Ledford JG, Latour AM, Snozaert JN, Bernier V,


**Address correspondence to:** Dr. Girolamo Calo, Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, via Fossato di Mortara, 19, 44100 Ferrara, Italy. E-mail: g.calonif@unife.it